{
    "2021-12-02": [
        [
            {
                "time": "2023-10-15",
                "original_text": "Aurinia Pharma Surges Again As Novartis Joins List Of Potential Suitors",
                "features": {
                    "keywords": [
                        "Aurinia",
                        "Pharma",
                        "Surges",
                        "Novartis",
                        "Potential Suitors"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Why Aurinia Pharmaceuticals Stock Bolted Higher Today",
                "features": {
                    "keywords": [
                        "Aurinia",
                        "Pharmaceuticals",
                        "Stock",
                        "Bolted",
                        "Higher"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off Today",
                "features": {
                    "keywords": [
                        "AUPH",
                        "Stock",
                        "Novartis",
                        "Takeover",
                        "Talk",
                        "Aurinia",
                        "Pharma",
                        "Shares",
                        "Taking Off"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "10 Dividend Stocks to Buy According to Bernard Hornâ€™s Polaris Capital",
                "features": {
                    "keywords": [
                        "Dividend",
                        "Stocks",
                        "Buy",
                        "Bernard Horn",
                        "Polaris Capital"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Novartis expects new drugs to boost sales by at least 4% until 2026",
                "features": {
                    "keywords": [
                        "Novartis",
                        "new drugs",
                        "boost",
                        "sales",
                        "4%",
                        "2026"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms",
                "features": {
                    "keywords": [
                        "Novartis",
                        "R&D",
                        "growth profile",
                        "in-market brands",
                        "pipeline assets",
                        "technology platforms"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}